These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11291253)

  • 21. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management issues in chronic viral hepatitis: hepatitis C.
    Sievert W
    J Gastroenterol Hepatol; 2002 Apr; 17(4):415-22. PubMed ID: 11982722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
    Gheorghe L; Baculea S
    Hepatogastroenterology; 2010; 57(101):939-44. PubMed ID: 21033255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
    Sagmeister M; Wong JB; Mullhaupt B; Renner EL
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):483-8. PubMed ID: 11396525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
    Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.
    Mangi A; Villani MR; Minerva N; Leandro G; Bacca D; Cela M; Carretta V; Attino V; Ventrella F; Giangaspero A; Andriulli A
    J Hepatol; 2001 Mar; 34(3):441-6. PubMed ID: 11322207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with interferon and ribavirin for chronic hepatitis C.
    Davis GL
    Clin Liver Dis; 1999 Nov; 3(4):811-26. PubMed ID: 11291252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
    Nyberg L; Albrecht J; Glue P; Gianelli G; Zambas D; Elliot M; Conrad A; McHutchison J
    J Clin Gastroenterol; 1999 Jun; 28(4):313-6. PubMed ID: 10372927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
    Annemans L; Warie H; Nechelput M; Peraux B
    Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ribavirin plus interferon versus interferon for chronic hepatitis C.
    Brok J; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005445. PubMed ID: 16034976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
    Westin J; Lindh M; Nenonen N; Lagging LM; Norkrans G; Wejstål R
    Scand J Infect Dis; 2001; 33(2):110-5. PubMed ID: 11233844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.
    Iwasaki Y; Tanaka H; Ikeada H; Okamoto R; Araki Y; Yabushita K; Kobashi H; Kariyama K; Kawaguchi M; Takaguchi K; Sakata T; Ando M; Sakaguchi K; Aoki N; Shiratori Y
    Scand J Gastroenterol; 2011 Jan; 46(1):79-90. PubMed ID: 20822376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
    Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.
    Azzaroli F; Accogli E; Nigro G; Trere D; Giovanelli S; Miracolo A; Lodato F; Montagnani M; Tamé M; Colecchia A; Mwangemi C; Festi D; Roda E; Derenzini M; Mazzella G
    World J Gastroenterol; 2004 Nov; 10(21):3099-102. PubMed ID: 15457551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.